MA54741A - Composés thiényl-aniline destinés au traitement d'affections de la peau - Google Patents
Composés thiényl-aniline destinés au traitement d'affections de la peauInfo
- Publication number
- MA54741A MA54741A MA054741A MA54741A MA54741A MA 54741 A MA54741 A MA 54741A MA 054741 A MA054741 A MA 054741A MA 54741 A MA54741 A MA 54741A MA 54741 A MA54741 A MA 54741A
- Authority
- MA
- Morocco
- Prior art keywords
- thienyl
- treatment
- skin conditions
- aniline compounds
- aniline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769832P | 2018-11-20 | 2018-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54741A true MA54741A (fr) | 2021-11-24 |
Family
ID=70773567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054741A MA54741A (fr) | 2018-11-20 | 2019-11-20 | Composés thiényl-aniline destinés au traitement d'affections de la peau |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12466818B2 (fr) |
| EP (1) | EP3911313A4 (fr) |
| JP (1) | JP7546297B2 (fr) |
| CN (2) | CN113498340A (fr) |
| AU (1) | AU2019384645B2 (fr) |
| CA (1) | CA3120352A1 (fr) |
| MA (1) | MA54741A (fr) |
| WO (1) | WO2020106305A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020106305A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composés thiényl-aniline destinés au traitement d'affections de la peau |
| EP3883552B1 (fr) | 2018-11-20 | 2025-04-09 | NFlection Therapeutics, Inc. | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| CN113660931B (zh) * | 2018-11-20 | 2024-10-11 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物 |
| CN113473986B (zh) | 2018-11-20 | 2024-10-11 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病萘啶酮苯胺化合物 |
| US11010862B1 (en) * | 2019-11-14 | 2021-05-18 | Advanced Micro Devices, Inc. | Reduced bandwidth tessellation factors |
| KR20240125577A (ko) | 2021-11-23 | 2024-08-19 | 엔플렉션 테라퓨틱스, 인코포레이티드 | 피롤로피리딘-아닐린 화합물의 제형 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4271164A (en) | 1979-04-16 | 1981-06-02 | Warner-Lambert Company | 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives |
| GB9420168D0 (en) | 1994-10-06 | 1994-11-23 | Boots Co Plc | Therapeutic agents |
| ES2229515T3 (es) | 1997-07-01 | 2005-04-16 | Warner-Lambert Company Llc | Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek. |
| ATE344791T1 (de) | 1997-07-01 | 2006-11-15 | Warner Lambert Co | 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren |
| JP2910748B2 (ja) | 1997-11-12 | 1999-06-23 | 日本電気株式会社 | 異質同軸部材の端面の球状加工装置及びその方法 |
| JP2002534515A (ja) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | 1−複素環置換されたジアリールアミン |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| AU2003225161A1 (en) | 2002-04-24 | 2003-11-10 | Koo, Han-Mo | Enhancement of human epidermal melanogenesis |
| RU2324695C2 (ru) | 2002-08-06 | 2008-05-20 | Ф.Хоффманн-Ля Рош Аг | 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38 |
| KR101190912B1 (ko) | 2003-11-19 | 2012-10-12 | 어레이 바이오파마 인크. | Mek의 헤테로시클릭 억제제 및 그의 사용 방법 |
| JP2008503446A (ja) | 2004-05-06 | 2008-02-07 | プレキシコン,インコーポレーテッド | Pde4b阻害剤及びその使用 |
| KR100883289B1 (ko) | 2004-06-11 | 2009-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2h-피리도[2,3-d]피리미딘 유도체 및 관련 화합물 |
| US7674907B2 (en) | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
| ES2444866T3 (es) | 2004-10-20 | 2014-02-27 | Merck Serono Sa | Derivados de 3-arilamino piridina |
| MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
| WO2007123939A2 (fr) | 2006-04-19 | 2007-11-01 | Laboratoires Serono S.A. | Nouveaux arylamino n-hétéraryles en tant qu'inhibiteurs de mek |
| GB0616214D0 (en) | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
| CA2658725A1 (fr) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Procedes d'utilisation de modulateurs pi3k etmek |
| CA2660546A1 (fr) | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Composes aza-benzofuranyle et leurs procedes d'utilisation |
| WO2008024724A1 (fr) | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Composés aza-benzothiophényle et leurs procédés d'utilisation |
| CA2666398C (fr) | 2006-10-17 | 2015-08-18 | Ed Kisak | Gel de diclofenac |
| EP2113500A1 (fr) | 2006-10-31 | 2009-11-04 | Takeda Pharmaceutical Company Limited | Inhibitêur du kinàse MAPK/ERK |
| CA2672327A1 (fr) | 2006-11-30 | 2008-06-05 | Genentech, Inc. | Composes azaindolyliques et procedes d'utilisation de ceux-ci |
| JP5592253B2 (ja) | 2007-05-11 | 2014-09-17 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 過剰増殖性疾患およびマイトジェン細胞外キナーゼ活性関連性疾患を治療するための置換フェニルアミノ−ベンゼン誘導体 |
| US20080312307A1 (en) * | 2007-05-25 | 2008-12-18 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
| CA2708176A1 (fr) | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Azaindolizines et procedes d'utilisation |
| GB0801080D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
| GB0801081D0 (en) | 2008-01-21 | 2008-02-27 | Ucb Pharma Sa | Therapeutic agents |
| WO2009093008A1 (fr) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Dérivés de thiénopyridine utilisés comme inhibiteurs de mek |
| GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
| CN102458402B (zh) | 2009-06-12 | 2013-10-02 | 百时美施贵宝公司 | 用作激酶调节剂的烟酰胺化合物 |
| DE102010012594A1 (de) | 2010-03-23 | 2011-09-29 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten |
| US9422262B2 (en) | 2010-09-24 | 2016-08-23 | The Broad Institute, Inc. | Compounds and methods for treating diseases mediated by protease activated receptors |
| CN103189062B (zh) | 2010-11-05 | 2016-03-23 | 霍夫曼-拉罗奇有限公司 | 活性药物化合物用于治疗中枢神经系统病症的用途 |
| WO2012099968A1 (fr) | 2011-01-19 | 2012-07-26 | The Trustees Of The University Of Pennsylvania | Compositions et procédés de traitement de maladies associées à un cancer de la peau |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| EP2757092A4 (fr) | 2011-06-17 | 2015-09-23 | Sinochem Corp | Composés de cyanoaniline substitués, leur préparation et leur utilisation |
| US9357781B2 (en) | 2013-05-03 | 2016-06-07 | Inscent, Inc. | Honeybee repellents and uses thereof |
| US10835513B2 (en) | 2013-06-28 | 2020-11-17 | The Regents Of The University Of California | Methods and treatments for the learning and memory deficits associated with Noonan syndrome |
| US9572828B2 (en) | 2013-07-18 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
| CN105384754B (zh) | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| EP3383912A4 (fr) | 2015-11-30 | 2019-11-06 | Ignyta, Inc. | Formulations topiques |
| EP3301094A1 (fr) | 2016-09-30 | 2018-04-04 | Mutabilis | Nouveaux composés hétérocycliques et leur utilisation dans la prévention ou le traitement d'infections bactériennes |
| JP7212956B2 (ja) | 2017-05-19 | 2023-01-26 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置用のピロロピリジン-アニリン化合物 |
| ES2913213T3 (es) | 2017-05-19 | 2022-06-01 | Nflection Therapeutics Inc | Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos |
| WO2019139970A1 (fr) | 2018-01-09 | 2019-07-18 | Duke University | Administration topique d'agents inhibiteurs de mek pour le traitement de troubles cutanés |
| WO2020101878A2 (fr) | 2018-10-29 | 2020-05-22 | The Johns Hopkins University | Traitement de rasopathie |
| WO2020106304A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Formulations topiques |
| CN113473986B (zh) | 2018-11-20 | 2024-10-11 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病萘啶酮苯胺化合物 |
| EP3883552B1 (fr) | 2018-11-20 | 2025-04-09 | NFlection Therapeutics, Inc. | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| WO2020106305A1 (fr) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Composés thiényl-aniline destinés au traitement d'affections de la peau |
| CN113645964B (zh) | 2018-11-20 | 2024-10-11 | 恩福莱克逊治疗有限公司 | 用于胎记治疗的芳基苯胺和杂芳基苯胺化合物 |
| CN113660931B (zh) | 2018-11-20 | 2024-10-11 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物 |
| JP2023547040A (ja) | 2020-09-24 | 2023-11-09 | エヌフレクション セラピューティクス インコーポレイテッド | ピロロピリジン-アニリン化合物による、認知機能不全の処置方法 |
| CN117157065A (zh) | 2021-01-21 | 2023-12-01 | 恩福莱克逊治疗有限公司 | 吡咯并吡啶-苯胺化合物的晶型 |
| AU2022210443A1 (en) | 2021-01-21 | 2023-09-07 | Nflection Therapeutics, Inc. | Processes for preparing pyrrolopyridine-aniline compounds |
-
2019
- 2019-11-20 WO PCT/US2019/000067 patent/WO2020106305A1/fr not_active Ceased
- 2019-11-20 US US17/294,779 patent/US12466818B2/en active Active
- 2019-11-20 AU AU2019384645A patent/AU2019384645B2/en active Active
- 2019-11-20 CA CA3120352A patent/CA3120352A1/fr active Pending
- 2019-11-20 EP EP19887349.9A patent/EP3911313A4/fr active Pending
- 2019-11-20 JP JP2021527910A patent/JP7546297B2/ja active Active
- 2019-11-20 CN CN201980089585.XA patent/CN113498340A/zh active Pending
- 2019-11-20 MA MA054741A patent/MA54741A/fr unknown
- 2019-11-20 CN CN202311548396.9A patent/CN117551073A/zh active Pending
-
2025
- 2025-10-13 US US19/356,850 patent/US20260167631A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113498340A (zh) | 2021-10-12 |
| JP2022510586A (ja) | 2022-01-27 |
| US12466818B2 (en) | 2025-11-11 |
| CN117551073A (zh) | 2024-02-13 |
| US20260167631A1 (en) | 2026-06-18 |
| EP3911313A4 (fr) | 2022-10-12 |
| JP7546297B2 (ja) | 2024-09-06 |
| US20220204486A1 (en) | 2022-06-30 |
| CA3120352A1 (fr) | 2020-05-28 |
| EP3911313A1 (fr) | 2021-11-24 |
| AU2019384645B2 (en) | 2025-08-21 |
| WO2020106305A1 (fr) | 2020-05-28 |
| AU2019384645A1 (en) | 2021-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
| EP3911313A4 (fr) | Composés thiényl-aniline destinés au traitement d'affections de la peau | |
| EP3883567A4 (fr) | Composés naphthyridinone-aniline destinés au traitement d'affections de la peau | |
| ECSP21093541A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| MA52575A (fr) | Pansement pour le traitement de la peau endommagée | |
| EP3883552A4 (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
| EP3448389A4 (fr) | Composés de quinazoline et d'indole destinés au traitement de troubles médicaux | |
| IL271046A (en) | Compounds for treating huntington's disease | |
| IL286340A (en) | Topical formulations for treatment of peripheral neuropathies | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| EP3784260A4 (fr) | Compositions pour le traitement d'affections cutanées | |
| PL3405215T3 (pl) | Sposoby leczenia choroby danona i innych zaburzeń autofagii | |
| MA55143A (fr) | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau | |
| EP3950686A4 (fr) | Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer | |
| EP3852745A4 (fr) | Composés destinés au traitement de certaines leucémies | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| EP3790563A4 (fr) | Compositions permettant le traitement d'affections cutanées | |
| EP3664812A4 (fr) | Compositions topiques pour la peau destinées au traitement de l'érythème ou de l'inflammation cutanée | |
| EP3672587A4 (fr) | Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques | |
| EP3959213C0 (fr) | Inhibiteurs de jak à base de pyrimidine pour le traitement de maladies de la peau | |
| EP3773632A4 (fr) | Méthodes de traitement de glioblastomes exprimant l'egfrviii | |
| EP3593803A4 (fr) | Composés destinés au traitement de maladies causées par l'accumulation d'oxalate | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| EP3927428A4 (fr) | Méthodes de traitement d'affections respiratoires |